Rapt Therapeutics (NASDAQ:RAPT) Upgraded by Wall Street Zen to “Hold” Rating

Rapt Therapeutics (NASDAQ:RAPT) was upgraded by Wall Street Zen to a “hold” rating in a report issued on Saturday.

RAPT has been the topic of several other research reports. Wells Fargo & Company downgraded Rapt Therapeutics from an “overweight” rating to an “equal weight” rating and set a $58.00 target price on the stock. in a research note on Tuesday, January 20th. Guggenheim cut Rapt Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 20th. Barclays cut shares of Rapt Therapeutics from an “overweight” rating to an “equal weight” rating and set a $58.00 price objective on the stock. in a research note on Wednesday, January 21st. Clear Str lowered shares of Rapt Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 20th. Finally, HC Wainwright downgraded shares of Rapt Therapeutics from a “buy” rating to a “neutral” rating and set a $58.00 price target on the stock. in a research report on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $48.44.

Rapt Therapeutics Stock Performance

RAPT opened at $58.02 on Friday. The business’s 50 day moving average is $49.94 and its 200-day moving average is $34.34. The stock has a market cap of $1.61 billion, a PE ratio of -5.25 and a beta of 0.49. Rapt Therapeutics has a twelve month low of $5.67 and a twelve month high of $58.02.

Institutional Investors Weigh In On Rapt Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of RAPT. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Rapt Therapeutics in the 4th quarter valued at about $46,000. Invesco Ltd. raised its holdings in shares of Rapt Therapeutics by 411.7% in the 1st quarter. Invesco Ltd. now owns 58,901 shares of the company’s stock worth $72,000 after purchasing an additional 47,391 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in Rapt Therapeutics during the fourth quarter valued at approximately $153,000. AQR Capital Management LLC acquired a new stake in Rapt Therapeutics during the first quarter valued at approximately $188,000. Finally, Bank of Nova Scotia bought a new stake in Rapt Therapeutics during the fourth quarter worth approximately $227,000. 99.09% of the stock is currently owned by institutional investors.

Rapt Therapeutics Company Profile

RAPT Therapeutics, Inc (NASDAQ:RAPT) is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company’s research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.

The company’s lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma.